Dimensional Fund Advisors LP Buys 333,123 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Dimensional Fund Advisors LP raised its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 19.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,036,743 shares of the company’s stock after purchasing an additional 333,123 shares during the period. Dimensional Fund Advisors LP owned 1.54% of Organogenesis worth $5,702,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Pallas Capital Advisors LLC purchased a new stake in Organogenesis in the 2nd quarter worth approximately $38,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares in the last quarter. CWM LLC boosted its holdings in Organogenesis by 301.8% in the 2nd quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after buying an additional 19,242 shares during the period. Caxton Associates LP purchased a new stake in Organogenesis in the 1st quarter worth $88,000. Finally, Principal Financial Group Inc. bought a new stake in Organogenesis during the first quarter valued at about $100,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

ORGO opened at $2.99 on Wednesday. The company has a market capitalization of $396.38 million, a PE ratio of 74.77 and a beta of 1.60. The firm has a 50-day simple moving average of $2.76 and a two-hundred day simple moving average of $2.75. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22. Organogenesis Holdings Inc. has a 52 week low of $1.96 and a 52 week high of $4.70.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The business had revenue of $130.23 million for the quarter, compared to the consensus estimate of $122.48 million. Analysts forecast that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital initiated coverage on Organogenesis in a research report on Friday, June 28th. They set a “buy” rating and a $5.00 target price for the company.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.